1-4 of 4
Alexander R. Macalalad, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD
Journal: Blood
Blood (2012) 120 (21): 4447.
https://doi.org/10.1182/blood.V120.21.4447.4447
Published: 2012
Journal Articles

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD, PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD
Journal: Blood
Blood (2012) 120 (21): 4443.
https://doi.org/10.1182/blood.V120.21.4443.4443
Published: 2012
Journal Articles

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Stuart L. Goldberg, MD, Lei Chen, MD, PhD, Solveig G. Ericson, MD, PhD, Alexander R. Macalalad, MD, Annie Guerin, MSc, Nathan Liu, MPH, Michael Kaminsky, BSc, Eric Qiong Wu, PhD
Journal: Blood
Blood (2012) 120 (21): 1685.
https://doi.org/10.1182/blood.V120.21.1685.1685
Published: 2012
Journal Articles

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

James D. Griffin, MD, Annie Guerin, MSc, Lei Chen, MD, PhD, Alexander R. Macalalad, MD, Jiayuan Luo, MSc, Eric Qiong Wu, PhD
Journal: Blood
Blood (2012) 120 (21): 2796.
https://doi.org/10.1182/blood.V120.21.2796.2796
Published: 2012